Keith M Skubitz (Keith Skubitz)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Topics

Transcatheter Aortic Valve Replacement

Ejection Fraction

Top Venues

Cancer chemotherapy and pharmacology

BMC medical genomics

Clinical sarcoma research

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Natalie K Heater, Scott Okuno, Steven Robinson, Steven Attia, Mahesh Seetharam, Brittany L Siontis, Janet Yoon, Sant Chawla, Mohammed M Milhem, Varun V Monga, Keith M Skubitz, John Charlson, Angela C Hirbe, Mia C Weiss, Brian Andrew Van Tine, Mark Agulnik
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma. Journal of clinical medicine 12 (7) (2023)
Keith M Skubitz, Evidio Domingo-Musibay, Bruce R Lindgren, Edward Y Cheng
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide. Cancers 14 (14) (2022)
Devon Miller, Jonathan A Livingston, Yeonhee Park, Kristi Posey, Sonia Godbole, Keith M Skubitz, Steven I Robinson, Mark Agulnik, Lara E Davis, Brian Andrew Van Tine, Angela C Hirbe, Amanda Parkes
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer medicine 11 (18) (2022)
Nuttavut Sumransub, Paari Murugan, Shelly Marette, Denis R Clohisy, Keith M Skubitz
Multiple malignant tumors in a patient with familial chordoma, a case report. BMC medical genomics 14 (1) (2021)
Malvi Savani, Katti Woerner, Lihong Bu, Mark Birkenbach, Keith M Skubitz
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review. Cancer chemotherapy and pharmacology 87 (2) (2021)
Daniel F Pease, Bruce A Peterson, Scott Gilles, Maria K Hordinsky, Kimberly A Bohjanen, Keith M Skubitz
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity. Cancer chemotherapy and pharmacology 84 (1) (2019)
Keith M Skubitz
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors. The oncologist 24 (7) (2019)
Malvi Savani, Paari Murugan, Keith M Skubitz
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure. Clinical sarcoma research 9 (2019)
Brian L Samuels, Sant P Chawla, Neeta Somaiah, Arthur P Staddon, Keith M Skubitz, Mohammed M Milhem, Pamela E Kaiser, David C Portnoy, Dennis A Priebat, Mark S Walker, Edward J Stepanski
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123 (23) (2017)
Keith M Skubitz, Anne H Blaes, Suma H Konety, Gary S Francis
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer chemotherapy and pharmacology 80 (4) (2017)